JCOGの基本情報 > 研究実績 > 食道がんグループ

JCOGの基本情報食道がんグループ

更新日:2015年12月18日

  1. 論文
    1. 委員会承認の治療研究
      JCOG8201
      T Iizuka, H Ide, T Kakegawa, et al.: Preoperative Radioactive Therapy for Esophageal Carcinoma: Randomized Evaluation Trial in Eight Institutions. Chest. 3: 1054-1058, 1988.
      JCOG8503
      Japanese Esophageal Oncology Group: A Comparison of Chemotherapy and Radiotherapy as Adjuvant Treatment to Surgery for Esophageal Carcinoma. Chest. 104: 203-207, 1993.
      JCOG8703
      T Iizuka, T Kakegawa, H Ide, et al.: Phase II Evaluation of Combined Cisplatin and Vindesine in Advanced Squamous Cell Carcinoma of the Esophagus: Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 21(3) : 176-179, 1991.
      JCOG8806
      N Ando, T Iizuka, T Kakegawa, et al.: A Randomized Trial of Surgery with and without Chemotherapy for Localized Squamous Carcinoma of the Thoracic Esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 114: 205-209, 1997.
      JCOG8807
      T Iizuka, T Kakegawa, H Ide, et al.: Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 22(3) : 172-176, 1992.
      JCOG9204
      N Ando, T Iizuka, H Ide, et al : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan ClinicalOncology Group Study ?JCOG 9204. J Clin Oncol. 21:4592-4596, 2003
      JCOG9407
      K Hayashi, N Ando, H Watanabe, et al.: Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 31(9) :419-423, 2001.
      JCOG 9516
      K Ishida, N Ando, S Yamamoto, et al.: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG)/ Japan Clinical Oncology Group trial (JCOG9516): Jpn J Clin Oncol 34(10):1-5, 2004.
      JCOG 9708
      H Kato, A Sato, H Fukuda, et al.: A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 39:638-643, 2009.
      JCOG9905-DI
      K Kato, K Muro, N Ando, et al.: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) Esophagus 11(3): 183-188, 2014.
      JCOG 9907
      N Ando, H Kato, H Igaki, et al.: A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-fluorouracil versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Ann Surg Oncol. 19(1): 68-74, 2012.
      JCOG0303
      M Shinoda, N Ando, K Kato, et al.: A Randomized study of Low versus Standard-dose Chemoradiotherapy for Unresectable Esophageal Squamous Cell Carcinoma (JCOG0303). Cancer Sci. 106(4): 407-412, 2015.
      JCOG0604
      M Tahara, N Fuse, J Mizusawa, et al.: Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). Cancer Sci. 106(10): 1414-1420, 2015.
      JCOG0807
      S Hironaka, Y Tsubosa, J Mizusawa, et al.: Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 105(9):1189-1195, 2014.
      JCOG1109
      K Nakaura, K Kato, H Igaki, et al.: Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study) Jpn J Clin Oncol. 43(7): 752-755. 2013.
      JCOG1306-A
      K Kataoka, K Nakamura, J Mizusawa, et al.: Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. Br J Surg. 102(9): 1088–1096, 2015.
      JCOG1314
      K Kataoka, T Tsushima, J Mizusawa, et al.: A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Jpn J Clin Oncol. 45(5): 494-498, 2015.
    2. グループ代表者管理の治療研究
      なし
    3. 附随研究等
      • K Ishida, T Iizuka, N Ando, et al.: Phase II Study of Chemotherapy for Advanced Squamous Cell Carcinoma of the Thoracic Esophagus: Nine Japanese Institutions Trial. Jpn J Clin Oncol. 26: 310-315, 1996.
      • Nishimaki, O Tanaka, N Ando, et al.: Evaluation of the Accuracy of Preoperative Staging in Thoracic Esophageal Cancer. Ann Thorac Surg. 68: 2059-2064, 1999.
      JCOG9907
      M Hirao, N Ando, T Tsujinaka, et al.: Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 98(12):1735-1741, 2011
      T Yokota , N Ando , H Igaki, et al.: Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer(JCOG9907). Oncology. 89(3):143-151, 2015.
      T Yokota, H Igaki, K Kato, et al.: Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial. Int J Clin Oncol. Sep 3, 2015.
      K Kataoka, K Nakamura, J Mizusawa, et al.: Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. Br J Surg. 102(9):1088-1096, 2015.
      JCOG0303
      N Sanuki, S Ishikura, M Shinoda, et al.: Radiotherapy Quality Assurance Review for A Multi-center Randomized Trial of Locally Advanced Esophageal Cancer: The Japan Clinical Oncology Group (JCOG) Trial 0303. Int J Clin Oncol. 17(2):105-111, 2012.
      JCOG0502
      I Nozaki, K Kato, H Igaki, et al.: Evaluation of safety profile of thoracoscopic esophagectomy for T1bN0M0 cancer using data from JCOG0502: a prospective multicenter study. Surg Endosc. 29:3519–3526, 2015.
      Y Akutsu, K Kato, H Igaki, et al.: The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: From the results of JCOG0502, a prospective multicenter study. Ann Surg (in press).
    4. 総説・解説
      • 安藤暢敏:進行食道癌に対する集学的治療. 日消外会誌. 314:138-142, 1998.
      • 安藤暢敏:術前化学放射線療法. 消化器病セミナー. 80:53-61, 2000.
      • 安藤暢敏, 石 志紘:食道癌の化学療法. 日消外会誌. 103:359-363, 2002.
      • 安藤暢敏:切除可能食道癌の手術補助療法-有効か否か-. 臨床外科. 57:199-203, 2002.
      • T Kodaira, N Fuwa, M Shinoda, et al : Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol. 26:392-397, 2003.
      • H Takeuchi, S Ozawa, N Ando, et al : Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradio- therapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 10:792-800, 2003.
      • Y Kinoshita, H Udagawa, K Tsutsumi, et al : Esophageal carcinoma with tracheal stenosisdue to tumor invasion and long survival after chemoradiotherapy. Diseases of the Esophagus 16:261-264, 2003.
      • Y Doki, O Ishikawa, T Kabuto, et al : Possible indication for surgical treatment of squamous cell carcinomas of the esophagus that involve the stomach. Surgery 133: 479-485, 2003.
      • S Ishikura, K Nihei, A Ohtsu, et al : Long-termtoxicity after definitive chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 21:2697-2702, 2003.
      • 安藤暢敏 :癌治療適応のパラダイムシフト -手術から非手術へー.日医雑誌 130:1015-1019, 2003.
      • 室 圭, 新井達広, 加藤抱一, 他:食道癌に対する根治的な放射線化学療法.臨床消化器内科. 18:1507-1514, 2003.
      • 中村 努, 井手博子, 江口礼紀, 他:進行食道癌に対するNedaplatin+5-FU化学放射線療法の治療成績.癌と化学療法. 30:803-807, 2003.
      • 宇田川晴司, 堤 謙二, 上野正紀, 他:切除断端陽性が疑われる食道癌に対する術前化学放射線療法の評価.日本外科系連合学会誌. 28:690-697, 2003.
      • 松原久裕, 落合武徳:外科におけるランダム化比較試験 (RCT)の問題点.外科. 65:1004-1010, 2003.
      • 石倉 聡:放射線治療の多施設共同研究におけるquality assuranceとquality control.血液・腫瘍科. 47: 388-392, 2003.
      • 梶山美明, 鶴丸昌彦, 岩沼佳見, 他:食道癌治療のControversy -外科の立場からー.癌と化学療法. 30:1225-1229, 2003
      • 佐藤道夫, 安藤暢敏:進行食道癌に対する化学療法. 外科. 66(11): 1254-1258, 2004.
      • H Igaki, Y Tachimori, H Kato.: Improved survival for patients with upper and/ or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg. 239:483-490, 2004.
      • 山名秀明:食道がんに対する術後補助化学療法の有効性. 血液・腫瘍科. 49(3):311-316, 2004.
      • T Nakamura, et al.: Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 188:261-266, 2004.
      • M Hirao, T Tsujinaka, et al.: Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. Dis Esophagus. 17(3): 247-250, 2004.
      • 安藤暢敏:がん治療のcontroversy 1)食道がんの治療選択:化学放射線療法 vs.外科的切除.臨床腫瘍内科学入門. 332-336, 2005.
      • 佐藤道夫, 安藤暢敏:食道癌治療の最前線 術前術後の化学療法. 消化器病セミナー. 99:85-95, 2005.
      • H Fujita, S Sueyoshi, H Yamana, et al.: Esophagectomy:Is it Necessary after Chemoradiotherapy for a Locally Advanced T4 Esophageal Cancer? Prospective Nonrandomized Trial Comparing Chemoradiotherapy with Surgery versus without Surgery. World J Surg. 29 : 25-31, 2005.
      • T Nakamura, K Hayashi, M Ota, et al.: Salvage surgery after definitive chemoradiotherapy for esophageal cancer. Esophagus. 2 : 123-128, 2005.
      • 三浦 昭順, 永井 鑑, 河野 辰幸, 他:進行・再発食道癌に対するsecond-lineとしての Docetaxel + Nedaplatin併用療法の検討. 日気食会報. 56 : 336-342, 2005.
      • M Yano, T Yasuda, H Miyata, et al.: Correlation Between Histological Effects on the Main Tumors and Nodal Status after Chemoradiotherapy for Squamous Cell Carcinoma of the Esophagus. J Surg Oncol. 89: 244-250, 2005.
      • S Kosugi, T Kanda, S Nakagawa, et al.: Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/ nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma. Scand J Gastroenterol. 40 : 886-892, 2005.
      • 平尾素宏, 藤谷和正, 辻仲利政, 他:根治切除不能進行食道癌に対するNedaplatin/Adriamycin/5-FU(NAF)併用療法のPhase I Study. Jpn J Cancer Chemother. 32 : 53-56, 2005.
      • M Shinoda, S Hatooka, S Mori, et al : Clinical Aspects of Multimodality Therapy for Resectable Locoregional Esophageal Cancer. Ann Thorac Cardiovasc Surg. 12:234-241, 2006.
      • T Nakamura, M Ota, K Hayashi, et al:Chemoradiotherapy With and Without Esophagectomy for Advanced Esophageal Cancer. Hepato-Gastroenterology. 53:705-709, 2006.
      • Y Tomimaru, M Yano, K Takachi, et al : Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol. 93:422-428, 2006.
      • A Ashida, N Boku, K Aoyagi, et al : Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol. 28:1345-1352, 2006.
      • T Suwa, Y Kitagawa, T Sasaki, et al : Release of band cells from the bone marrow is impaired by preoperative chemoradiation in patients with esophageal carcinoma: increased risk of postoperative pneumonia. Langenbecks Arch Surg. 391:461-466, 2006.
      • S Kosugi, T Kanda, T Nishimaki, et al : Successful treatment for esophageal carcinoma with lung metastasis by induction chemotherapyfollowed by salvage esophagectomy: Report of a case. World J Gastroenterol. 12:4101-4103, 2006.
      • Y To, T Ohga, S Ito, et al: radical surgery and definitive chemoradiotherapy for patients with submucosal esophageal squamous cell carcinomas. Anticancer Res. 26:2487-2491, 2006.
      • N Ando : Postoperative adjuvant therapy for completely resected esophageal cancer. Difficult Decisions in Thoracic Surgery An Evidence-Based Approach (M Ferguson Ed.) 265-270, Springer 2007.
      • 南出純二, 青山法夫, 高田 賢, 他:食道癌に対するSecond-Line ChemotherapyとしてのCisplatin, 5-FU, Docetaxel併用療法の検討.癌と化学療法.34:49-52,.2007.
      • H Yamana, T Tanaka, H Fujita, et al:Second-Line Combination Chemotherapy with Docetaxel for Clisplatin-Pretreated Refractory Metastatic Esophageal Cancer:A Preliminary Report of Initial Experience. Chemotherapy. 53:449-453, 2007.
      • 中村 努, 大田正穂, 成宮孝祐, 他:予後よりみた食道癌に対する化学放射線療法後salvage手術の適応.癌の臨床. 53(10): 619-623, 2007.
      • H Matsubara :Salvage surgery for esophageal carcinoma after definitive chemoradiation therapy. Ann Thorac Cardiovasc Surgery.13(5): 293 - 295, 2007.
      • T Uno, K Isobe, H Mastubara, et al.:Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Dis Esophagus. 20(1): 12-18, 2007.
      • M Kanai, S Mastumoto, G Watanabe, et al.:Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol. 12(3):224-227, 2007.
      • S Takeuchi, A Ohtsu, K Minashi, et al.:A Retrospective Study of Definitive Chemoradiotherapy for Elderly Patients With Esophageal Cancer. Am J of Clin Oncol. 30(6):607-611, 2007.
      • 竹内 裕也, 北川 雄光, 安藤 暢敏, 他:胸部食道癌に対する根治的化学放射線療法後salvage手術の検討.癌の臨床. 53(10):599-604, 2007.
      • T Tanabe, T Kanda, S Kosugi, et al.:Extranodal Spreading of Esophageal Squamous Cell Carcinoma:Clinicopathological Characteristics and Prognostic Impact. World J Surg. 31:2192-2198,2007.
      • 佐藤 弘, 坪佐 恭宏, 朴 成和, 他:胸部食道癌に対する根治目的放射線化学療法後のsalvage手術の意義と適応について.癌の臨床.53(10):635-639, 2007.
      • T Shiratori, S Okazumi, H Matsubara, et al.:Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg. 206(1):48-56, 2008.
      • T Nakajima, T Ura, Y Ito, et al.: A Phase I Trial of 5-fluorouracil with Cisplatin and Concurrent Standard-dose Radiotherapy in Japanese Patients with Stage II/III Esophageal Cancer. Jpn J Clin Oncol. 39: 37-42, 2009.
      • H Akita, Y Doki, M Yano, et al.: Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus. 22: 291-297, 2009.
      • M Yano, M Motoori, K Tanaka, et al.: Assessment of neoadjuvant chemotherapy for patients with advanced squamous cell carcinoma of the esophagus. Esophagus. 6: 111-116, 2009.
      • S Yamamoto, R Ishihara, M Motoori, et al.: Endoscopic classification of local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus. 6: 243-248, 2009
      • Y Akutsu, H Matsubara, K Shuto, et al.: Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 33: 1002-1009, 2009.
      • R Ishihara, S Yamamoto, H Iishi, et al.: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 76: 123-129, 2010.
      • S Yamamoto, R Ishihara, M Motoori , et al.: Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Am J Gastroenterol . 106(6): 1048-1054, 2011.
      • M Motoori, M Yano, T Yasuda, et al.: Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery. Esophagus. 8:81-87,2011.
      • R Ishihara, S Yamamoto, H Iishi, et al: Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol . 17(3):225-232, 2012.
      • M Motoor , M Yano, R Ishihara, et al.: Comparison Between Radical Esophagectomy and Definitive Chemoradiotherapy in Patients with Clinical T1bN0M0 Esophageal Cancer. Ann Surg Oncol. 19(7): 2135-2141, 2012.
      • Y Kitagawa, N Ando, K Nakamura, et al.: The Role of Adjuvant Chemotherapy for Localized Squamous Cell Esophageal Cancer: Current Japanese Standard and the Unending Role of the Drawing Board. Ann Surg Oncol. 19(5): 1425-1427, 2012.
      • H Takeuchi, H Kawakubo, F Takeda, et al.: Sentinel Node Navigation Surgery in Early-Stage Esophageal Cancer. Ann Thorac Cardiovasc Surg 18(4): 306-313, 2012.
      • 廣中秀一 : 5.食道がん.What’s New in Oncology. 南山堂. 369-379, 2012.
      • 廣中秀一 : 28.食道がん.新臨床腫瘍学 改訂第3版. 南江堂. 381-387, 2012.
      • 廣中秀一 : 食道癌周術期補助化学(放射線)療法の現状と新展開.臨牀消化器内科. 28(3):267-272, 2013.
      • 竹内裕也,川久保博文,中村理恵子,他 : 食道癌. 消化器外科. 35(6): 947-954, 2012.
      • 竹内裕也,北川雄光 : 食道癌化学療法. 外来癌化学療法. 3(2): 26-30, 2012.
      • 川久保博文,竹内裕也,北川雄光 : 食道癌の治療. 臨床外科. 67(11): 102-106, 2012.
      • 廣中秀一: 食道がん.抗悪性腫瘍薬安全使用マニュアル. 医薬ジャーナル社. 442-450, 2014.
      • 廣中秀一: 食道がん.あらゆる症例に対応できる!消化器がん化学療法.羊土社. 50-57,2015.
      • 廣中秀一: 化学療法 臨床食道癌 南江堂. 220-221,2015.
      • 廣中秀一: 食道がん.新臨床腫瘍学 改訂第4版 南江堂. 374-378, 2015.
      • 三梨桂子, 廣中秀一: 進行食道癌に対する最新の治療戦略とその成果─放射線化学療法の位置づけ─. Medical Practice 30(7): 1238-1240, 2013.
      • 加藤健: 食道がんに対する治療~術前化学療法か?化学放射線療法か?. 腫瘍内科. 15: 33-37, 2015.
      • 加藤健: 術前術後補助療法『臨床食道学』南江堂. 215-219, 2015.
      • 丸木雄太, 加藤健: 食道がんstageIB/II/IIIに対する集学的治療の考え方. 腫瘍内科. (16)4: 306-311, 2015.
      • 石本詩子, 加藤健: 進行・再発食道癌に対する薬物療法の基本レジメンと進め方. 消化器の臨床. 18(5), 2015.
  2. 主な学会発表
    1. 委員会承認の治療研究
      JCOG8806
      N Ando, T Iizuka, T Kakegawa, et al.: A Randomized Trial Comparing Surgery to Surgery plus Postoperative Chemotherapy for Localized Squamous Carcinoma of the Thoracic Esophagus: The Japan Clinical Oncology Group Study. The 34th Annual Meeting of the American Society of Clinical Oncology. May 1998.
      JCOG9204
      N Ando, T Iizuka, H Ide, et al.: A randomized trial of surgery alone vs surgery plus postoperative chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study (JCOG9204). The 35th Annual Meeting of the American Society of Clinical Oncology. May 1999.
      JCOG9905-DI
      K Muro, N Ando, T Nishimaki, et al.: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905). The 39 Annual Meeting of the American Society of Clinical Oncology. May 2003.
      JCOG9708
      加藤抱一, 山名秀明, 宇田川晴司, 他:ワークショップ9「食道sm癌の治療戦略」:Stage I 食道がんに対する放射線・抗がん剤同時併用療法の有用性. 第40回日本癌治療学会. 2002年10月.
      H Kato, H Udagawa, A Togo, et al.: A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: The Japan Clinical Oncology Group study (JCOG 9905). The 39 Annual Meeting of the American Society of Clinical Oncology. May 2003.
      JCOG9907
      N Ando, H. Kato, M. Shinoda, et al.:A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907).Gastrointestinal Cancer Symposium. Jan 2008.
      H Igaki, H Kato, N Ando, et al.:A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907).ASCO Annual Meeting. Jun 2008.
      JCOG0303
      M. Shinoda, N Ando, H Kato, et al.:A multicenter randomized phase II (rPII)/ III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). The 46 Annual Meeting of the American Society of Clinical Oncology. May 2010.
      篠田雅幸,安藤暢敏,石倉 聡, 他:食道がんを対象とした多施設共同研究の課題-JCOG0303を通して-. 第64回日本食道学会学術集会. 2010年8月.
      JCOG0807
      広中秀一, 坪佐恭宏, 浜本康夫, 他:切除不能/再発食道癌に対するDCF療法の臨床第I/II相試験(JCOG0807).第64回 日本食道学会学術集会. 2010年8月.
      T Kii, S Hironaka, Y Tsubosa, et al : A phase I/II study of biweekly docetaxel (D) with CDDP plus 5-FU (CF) for advanced esophageal cancer (AEC) (JCOG0807). 第11回日本臨床腫瘍学会学術集会. 2013年8月.
      S Hironaka, Y Tsubosa, J Mizusawa, et al.: A phase I/II study of biweekly docetaxel (D) in combination with fixed-dose cisplatin plus fluorouracil (CF) in patients (pts) with advanced esophageal cancer (AEC) (JCOG0807). J Clin Oncol. 31, 2013 (suppl; abstr e15016).
      S Hironaka, Y Tsubosa, J Mizusawa, et al.: A phase I/II study of biweekly docetaxel (D) combined with cisplatin and fluorouracil (CF) in patients (pts) with distant metastatic esophageal cancer (MEC)(JCOG0807). (Poster) The European Cancer Congress. Sep 2013.
      坪佐恭宏, 広中秀一, 水澤純基, 他: 切除不能または再発食道癌に対するDCF療法の臨床第I/II相試験(JCOG0807). 第51回日本癌治療学会学術集会. 2013年10月.
      JCOG1312-A
      片岡幸三, 水澤純基, 中村健一, 他:食道癌手術例における生存期間および周術期合併症に関する施設差の検討:JCOG9204/JCOG9907統合解析(JCOG1312-A). 第68回日本食道学会学術集会. 2014年7月.
      JCOG1314
      T Tsushima, K Kataoka, J Mizusawa. : MIRACLE: A multi-institutional randomized controlled phase III trial of CF with or without biweekly docetaxel for metastatic esophageal cancer (JCOG1314). 第13回日本臨床腫瘍学会学術集会. 2015年7月.
      JCOG1406A
      M Nomura, K Kato, J Mizusawa, et al.: Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A). Gastrointestinal Cancers Symposium. Jan 2015.
      M Nomura, K Kato, J Mizusawa, et al.: Comparison between NAC-S and CRT in overall survival for patients with esophageal squamous cell carcinoma (JCOG1406-A). 第13回日本臨床腫瘍学会学術集会. 2015年7月
      その他
      N Ando, T Iizuka, T Kakegawa, et al.: A randomized trial of surgery with and without chemotherapy for localized squamous cell carcinoma of the thoracic esophagus: JCOG study. The 7th World Congress of the International Society for Diseases of the Esophagus. Sep 1998.
      安藤暢敏, 飯塚紀文, 井手博子, 他:ワークショップ:外科における癌化学・免疫療法 ―state of the art― 食道癌に対する術後補助化学療法の再発予防効果 -JCOG Study― . 第100回日本外科学会総会. 2000年4月.
      N Ando: Multimodality treatment, Perspective. The 8th World Congress of the International Society for Diseases of the Esophagus. Sep 2001.
      H Udagawa, K Tsutsumi, Y Kinoshita, et al.: Evaluation of the efficacy of preoperative chemoradiotherapy to resectable esophageal cancer with suspicious positive surgical margin (cT4'). 9th ISDE INTERNATIONAL SOCIETY FOR DSEASES OF THE ESOPHAGUS, May 2004.
      松原久裕, 浦島哲郎, 岡住慎一, 他:パネルディスカッション「食道癌に対する集学的治療」:個別化治療をめざした食道癌に対する集学的治療. 第66回日本臨床外科学会総会. 2004年10月.
      安藤暢敏:教育セッション 食道癌.第45回日本癌治療学会総会.
    2. グループ代表者管理の治療研究
      浜本康夫, 橋本淳, 加藤健, 他 : 臨床病期II/III期食道癌に対する術前化学放射線療法+手術療法の実施可能性試験. 第66回日本食道学会学術集会. 2012年6月.
    3. 附随研究等
      JCOG9907
      T Yokota, N Ando, H Igaki, et al.: Prognostic factor for patients with advanced thoracic esophageal squamous cell carcinoma receiving preoperative cisplatim plus 5-fluorouracil(JCOG9907). ASCO Annual Meeting. May 2014.
      横田知哉, 井垣弘康, 北川雄光, 他: 切除可能・局所進行胸部食道扁平上皮癌における術前リンパ節診断精度の検討(JCOG9907副次的解析). 第68回日本食道学会学術集会. 2014年7月.
      H Hara, N Ando, H Igaki, et al.: The influence of chemotherapy-induced leucopenia (CIL) during preoperative chemotherapy (pre-Cx) on survival in esophageal squamous cell carcinoma (ESCC) from the results of JCOG9907. ESMO, Sep 2014.
      H Takeuchi, J Mizusawa, K Kato, et al.: Prognostic impact of postoperative morbidity after transthoracic esophagectomy for esophageal cancer: Analysis of JCOG9907 trial. ASCO Gastrointestinal Symposium. Jan 2015.
      片岡幸三, 竹内裕也, 水澤純基, 他: 食道癌術前化学療法例における周術期合併症と予後の関連についての検討;JCOG9907副次的解析. 第69階日本食道学会学術集会. 2015年7月.
      JCOG0303
      S Ishikura, M Shinoda, K Nakamura, et al.: Patterns of failure after definitive chemoradiotherapy for unresectable carcinoma of the thoracic esophagus: Secondary analyses of the Japan Clinical Oncology Group (JCOG) 0303 trial. The 53rd ASTRO Annual Meeting, Oct 2011.
      浜本康夫, 水澤純基, 原浩樹, 他:JCOG0303登録例における治療成績の施設間差の検討. 第68回日本食道学会学術集会. 2014年7月.
      對馬隆浩, 水澤純基, 中村健一, 他:局所進行胸部食道癌根治的化学放射線療法(JCOG0303)における食道瘻の検討. 第68回日本食道学会学術集会. 2014年7月.
      奥野達哉, 篠田雅幸: 局所進行食道癌化学放射線療法における予後因子の検討 (JCOG0303附随研究).第22回JDDW. 2014年10月.
      T Okuno, J Mizusawa, K Kato, et al.: Glasgow Prognostic Score and esophageal stenosis are predictive and prognostic factors of long-term outcome in locally advanced unresectable esophageal cancer patients treated with chemoradiotherapy (JCOG0303). ASCO Gastrointestinal cancer symposium. Jan 2015.
      JCOG0502
      I Nozaki, K Kato, H Igaki, et al.: Safety profile of thoracoscopic esophagectomyfor esophageal cancer compared with traditional thoracotomy from the results of JCOG0502:a randomaized trial of esophagectomy versus chemoradiotherapy. ASCO Gastrointestinal cancer symposium. Jan 2014.
      野崎功雄, 加藤健, 井垣弘康, 他:T1bN0食道癌に対する胸腔鏡下食道切除の安全性(JCOG0502附随研究). 第68回日本食道学会学術集会. 2014年7月.
      Y Akutsu, K Kato, H Igaki, et al.: The prevalence of lymph node metastases in clinical T1N0 thoracic esophageal cancer: the JCOG0502 randomized trial. ASCO Gastrointestinal cancer symposium. Jan 2015.
      K Kato, H Igaki, Y Ito, et al.: Determination factors of patients' decision between surgery and chemoradiotherapy for stage I esophageal carcinoma. From the results of JCOG0502, a comparative study of the two modalities. ASCO Gastrointestinal cancer Symposium. Jan 2015.
      阿久津泰典,加藤健,井垣弘康,他: T1N0胸部食道癌における病理学的リンパ節転移状況の検討JCOG0502附随研究. –第69回日本食道学会学術集会. 2015年7月.
      加藤健, 井垣弘康, 伊藤芳紀, 他: 臨床病期I期食道癌患者の治療選択に影響を及ぼす因子;JCOG0502副次的解析. 第69階日本食道学会学術集会. 2015年7月.
      JCOG0807
      T Ura, S Hironaka, Y Tsubosa, et al. Early tumor shrinkage and deepness of response in patients with metastatic esophageal cancer receiving first-line treatment with DCF : Exploratory analysis of the JCOG 0807 trial. ASCO Gastrointestinal cancer Symposium. Jan 2015.
    4. 総説・解説
      • N Ando: Lymphadenectomy for esophageal cancer - Multidisciplinary therapy - wher does it fit? 10th ISDE INTERNATIONAL SOCIETY FOR DSEASES OF THE ESOPHAGUS 2. Adelaide, Feb 2006.
      • 安藤暢敏:教育講演「食道癌治療の現状と展望 -State of the Art-」第43回日本癌治療学会総会. 2005年10月.
      • H Takeuchi: Esophageal cancer. 13th World Congress of Endoscopic Surgery. Apr 2012.
      • K Kato: Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma with Salvage Treatment, “Debate and Summary Session”CCRT vs CCRT+OP: Esophageal Cancer (Yes/No). 10th Asian Clinical Oncology Society. Jun 2012.
      • K Kato: Bi- and tri-modality management of Esophageal Cancer. World Congress on Gastrointestinal Cancer. Aug 2012.
      • Y Ito, T E Nakajima, H Ishiyama, et al.: Phase II trial of 5-Fluorouracil in combination with Cisplatin and Concurrent Radiotherapy (50.4 Gy) with elective nodal irradiation for clinical stage II/III Esophageal Cancer. 54th ASTRO. Oct 2012.
      • 竹内裕也, 川久保博文, 西知彦, 他: 食道癌に対する新しい補助療法効果予測因子の検討. 第112回日本外科学会定期学術集会. 2012年4月.
      • 新原正大, 竹内裕也, 才川義朗, 他: cStageⅡ/Ⅲ食道癌の術前化学療法施行例に対する無再発生存の予後因子の検討. 第67回日本消化器外科学会総会. 2012年7月.
      • 竹内裕也, 北川雄光: 食道癌外科治療におけるエビデンス. 第67回日本消化器外科学会総会. 2012年7月.
      • 浜本康夫, 船越信介, 樋口肇, 他: 胸部食道癌に対する3剤併用レジメンによる化学療法. 第9回日本消化管学会総会学術集会. 2013年1月.
      • 木村祐輔, 岩谷岳, 秋山有史, 他:食道癌根治化学放射線療法後のSalvage surgeryの治療成績. 第74回臨床外科学会. 2012年11月.
      • 木村祐輔, 岩谷岳, 秋山有史, 他:食道癌に対する根治的放射線化学療法後の salvage lymphadenectomyの意義. 第65回日本胸部外科学会. 2012年10月.
      • 木村祐輔, 岩谷岳, 秋山有史, 他:食道癌に対する根治的放射線化学療法後のSalvage手術の治療成績. 第67回 日本消化器外科学会. 2012年7月.
      • 秋山有史, 木村祐輔, 岩谷岳, 他:進行食道癌に対するDCF療法の治療成績. 第112回日本外科学会. 2012年4月.
      • 秋山有史, 木村祐輔, 岩谷岳, 他:食道癌根治的化学放射線療法後のリンパ節再発に対するSalvage lymphadenectomyの検討. 第50回日本癌治療学会. 2012年10月.
      • 秋山有史, 木村祐輔, 岩谷岳, 他:進行食道癌に対するDCF療法による術前化学療法の検討. 第67回日本消化器外科学会. 2012年7月.
      • 秋山有史, 木村祐輔, 岩谷岳, 他:局所進行食道癌に対するDCF療法の治療成績. 第66回日本食道学会学術集会. 2012年6月.
      • 秋山有史, 木村祐輔, 岩谷岳, 他:進行食道癌に対するDCF療法の治療成績. 第112回日本外科学会. 2012年4月.
      • 加藤 健 : 食道癌化学療法の進歩と今後 シンポジウム 「食道がん治療の過去と未来」. 第50回日本癌治療学会学術集会. 2012年10月.
      • K Kato: Chemoradiotherapy: Role in Early Squamous Cell Cancer. 14th World Congress of the International Society for Diseases of the Esophagus. ISDE 2014 Congress Sep 2014.
      • K Kato: Definitive Chemoradiation for Esophageal Cancer 14th World Congress of the International Society for Diseases of the Esophagus. ISDE 2014 Congress Sep 2014.
      • 加藤健, 井垣弘康, 伊藤芳紀: 術前補助化学放射線療法. 第27回日本放射線腫瘍学会. パネルディスカッション「切除可能なII/III期食道癌に対する治療戦略」. 2014年12月.
トップへ戻る